Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

728
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
728
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

419
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
419
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.0K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.0K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

481
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
481
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

2.6K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.6K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Vivo Anti-Nociceptive Activity of Isoquercetin in Rats Supported by ADMET and Molecular Docking Analysis.

Chemistry & biodiversity·2026
Same author

Apixaban-Induced Tongue and Extremity Angioedema: A Case Report.

American journal of therapeutics·2026
Same author

Acetylation Variability in Elderly Tunisians: Implications for Isoniazid Dose Individualization.

Journal of clinical pharmacology·2026
Same author

Pioneering infection prevention and control education through simulation-based learning: impact on knowledge and skills in nursing students in Tunisia.

BMC nursing·2026
Same author

Atypical Presentation of Grade III Hand-Foot Syndrome in a Patient With Breast Cancer Receiving Docetaxel.

American journal of therapeutics·2026
Same author

Therapeutic Clozapine Monitoring Using Dose-Related Reference Range.

Therapeutic drug monitoring·2026

Related Experiment Video

Updated: Aug 8, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

Statin Associated Muscular Adverse Effects.

Rania Kammoun1, Ons Charfi1,2, Ghozlane Lakhoua1,2

  • 1National Center of Pharmacovigilance, 9 Avenue du Dr Zouhaier Essafi, 1006, Tunis, Tunisia.

Current Drug Safety
|February 27, 2023
PubMed
Summary

Statins can cause muscle problems, from mild pain to severe rhabdomyolysis. Early recognition of these statin-induced muscle adverse effects is crucial for patient safety.

Keywords:
Statinadverse drug reactionatorvastatincreatine kinasemyotoxicityrhabdomyolysis.

More Related Videos

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
13:51

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay

Published on: November 11, 2018

9.9K
Application of Chronic Stimulation to Study Contractile Activity-induced Rat Skeletal Muscle Phenotypic Adaptations
09:50

Application of Chronic Stimulation to Study Contractile Activity-induced Rat Skeletal Muscle Phenotypic Adaptations

Published on: January 25, 2018

6.8K

Related Experiment Videos

Last Updated: Aug 8, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
13:51

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay

Published on: November 11, 2018

9.9K
Application of Chronic Stimulation to Study Contractile Activity-induced Rat Skeletal Muscle Phenotypic Adaptations
09:50

Application of Chronic Stimulation to Study Contractile Activity-induced Rat Skeletal Muscle Phenotypic Adaptations

Published on: January 25, 2018

6.8K

Area of Science:

  • Pharmacovigilance
  • Clinical Pharmacology
  • Cardiovascular Disease Management

Background:

  • Statins are primary treatments for hyperlipidemia and cardiovascular disease prevention.
  • A known risk of statin therapy includes muscular adverse effects, ranging from elevated creatine kinase to rhabdomyolysis.

Purpose of the Study:

  • To characterize the epidemiological and clinical profiles of patients experiencing statin-associated muscular adverse effects.
  • To analyze the spectrum and timeline of these adverse events.

Main Methods:

  • Retrospective, descriptive study conducted over a decade (2010-2019).
  • Inclusion of all statin-associated muscular adverse effect cases reported to the Tunisian National Centre of Pharmacovigilance.
  • Data analysis of patient demographics, symptom presentation, and outcomes.

Main Results:

  • 22 cases of statin-associated muscular adverse effects were identified, representing 28% of all statin adverse events.
  • The mean patient age was 58.7 years, with a sex ratio of 1.6.
  • Manifestations included isolated creatine kinase elevation (12 cases), myalgia (5), myopathy (3), myositis (1), and rhabdomyolysis (1).
  • Adverse effects appeared between 7 days and 15 years post-initiation; withdrawal led to symptom resolution within 10 days to 18 months, though creatine kinase remained elevated in 7 cases.
  • Atorvastatin, simvastatin, rosuvastatin, and fluvastatin were the implicated statins.

Conclusions:

  • Prompt identification of muscle symptoms is essential to avert severe outcomes like rhabdomyolysis.
  • Further investigation is necessary to fully understand the mechanisms behind statin-induced muscle damage.